Evofem Biosciences, Inc. Quarterly Operating Lease, Right-of-Use Asset in USD from Q4 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Evofem Biosciences, Inc. quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q4 2018 to Q3 2024.
  • Evofem Biosciences, Inc. Operating Lease, Right-of-Use Asset for the quarter ending September 30, 2024 was $127K, a 15.9% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $127K -$24K -15.9% Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $114K -$3.19M -96.5% Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $59K -$3.84M -98.5% Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $106K -$4.3M -97.6% Dec 31, 2023 10-Q 2024-11-14
Q3 2023 $151K -$4.95M -97% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $3.3M -$1.74M -34.5% Jun 30, 2023 10-Q 2023-11-14
Q1 2023 $3.9M -$1.09M -21.8% Mar 31, 2023 10-Q 2023-06-16
Q4 2022 $4.41M -$989K -18.3% Dec 31, 2022 10-K 2024-03-27
Q3 2022 $5.1M -$660K -11.5% Sep 30, 2022 10-Q 2023-01-06
Q2 2022 $5.04M -$1.11M -18.1% Jun 30, 2022 10-Q 2022-08-12
Q1 2022 $4.99M -$1.51M -23.2% Mar 31, 2022 10-Q 2022-05-10
Q4 2021 $5.4M -$1.46M -21.3% Dec 31, 2021 10-K 2023-04-27
Q3 2021 $5.76M -$1.43M -19.9% Sep 30, 2021 10-Q 2021-11-15
Q2 2021 $6.15M +$1.13M +22.6% Jun 30, 2021 10-Q 2021-08-11
Q1 2021 $6.49M +$6.23M +2378% Mar 31, 2021 10-Q 2021-05-06
Q4 2020 $6.86M +$6.7M +4185% Dec 31, 2020 10-K 2022-03-10
Q3 2020 $7.2M +$6.88M +2185% Sep 30, 2020 10-Q 2020-11-09
Q2 2020 $5.02M +$4.53M +938% Jun 30, 2020 10-Q 2020-08-04
Q1 2020 $262K -$383K -59.4% Mar 31, 2020 10-Q 2020-05-06
Q4 2019 $160K +$160K Dec 31, 2019 10-K 2021-03-04
Q3 2019 $315K Sep 30, 2019 10-Q 2019-11-07
Q2 2019 $483K Jun 30, 2019 10-Q 2019-08-06
Q1 2019 $645K Mar 31, 2019 10-Q 2019-05-07
Q4 2018 $0 Dec 31, 2018 10-Q 2019-11-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.